Levels of dyslipidaemia and improvement in its management in England: Results from the Health Survey for England 2003

Clinical Endocrinology

Volumn 64, Issue 3, 2006, Pages 292-298

  Primatesta, Paola ^a   Poulter, Neil R ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; STROKE; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; ENGLAND; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEX DISTRIBUTION;

EID: 33644932647     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02459.x     Document Type: Article

References (24)

1. Downs J.R. Clearfield M. Weis S. Whitney E. Shapiro D.R. Beere P.A. Lagendorfer A. Stein E.A. Kruyer W. Gotto A.M. for the AFCAPS/TexCAPS Research group 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Journal of the American Medical Association 79 1615 1622
2. Cannon C.P. Braunwald E. Mccabe C.H. Rader D.J. Rouleau J.L. Belder R. Joyal S.V. Hill K.A. Pfeiffer M.A. Skene A.M. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators 2004 Intensive versus moderate lipid lowering with statins after acute coronary syndromes New England Journal of Medicine 350 1495 1504
3. Colhoun H.M. Betteridge J. Durrington P.N. Hitman G.A. Neil H.A.W. Livingstone S.J. Thomason M.J. Fuller J.H. on behalf of the CARDS investigators. 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 685 696
4. Sever P.S. Dahlof B. Poulter N.R. Wedel H. Beevers G. Cauldfield M. Collins R. Kjeldsen S.E. Kristinsson A. McInness G.T. Mehelsen J. Nieminen M. O'Brien E. for the ASCOT investigators. 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 1149 1158
5. Shepherd J. Blauw G.J. Murphy M.B. Bollen E. Buckley B.M. Cobbe S.M. Ford I. Gaw A. Hyland M. Jukema J.W. Kamper A.M. Macfarlane P.W. Meinders A.E. Norrie J. Packard C.J. Perry I.J. Stott D.J. Sweeney B.J. Twomey G. Westendorp R.G.J. on behalf of the PROSPER Study Group. 2002 Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Journal of the American Medical Association 287 3215 3222
6. Heart Protection Study Collaborative Group. 2002 MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 7 22
7. Primatesta P. Poulter N.R. 2000 Lipid concentrations and the use of lipid-lowering drugs: evidence from a national cross-sectional survey British Medical Journal 321 1322 1325
8. Sproston K. Primatesta P. eds ( 2004 Health Survey for England 2003 The Stationery Office London
9. Blake M. Deverill C. Prescott A. Primatesta P. Stamatakis E. 2004 Methodology and documentation Volume 3. In Sproston K. Primatesta P. Health Survey for England 2003 The Stationery Office London
10. Wood D. Davis M. Durrington P. Poulter N. McInnes G. Kirby M. Patel V. Potter J. Reckless J. Rees A. Sivers F. Williams B. Wray R. for the British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, and Stroke Association. 2005 Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart 91 Suppl. 5 V1 V52
11. Anderson K.M. Odell P.M. Wilson P.W.P. Kannel W.B. 1991 Cardiovascular disease profiles American Heart Journal 121 293 209
12. Haq I.U. Ramsay L.C. Yeo W.W. Jackson P.R. Wallis E.J. 1999 Is the Framingham risk function valid for Northern European population? A comparison of methods for estimating absolute coronary risk in high-risk men Heart 81 40 46
13. Williams B. Poulter N. Brown M. Davies M. Mcinnes G. Potter J. Sever P. McG Thom S. 2004 Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society 2004-BHS IV Journal of Human Hypertension 18 139 185
14. National Service Framework for Coronary Heart Disease. 2000 Modern Standards and Service Models The Stationery Office London
15. Yusuf S. Hawken S. Ounpuu S. Dans T. Avezum A. Lanas F. McQueen M. Budaj A. Pais P. Varigos J. Lisheng L. on behalf of the INTERHEART Study Investigators 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 937 952
16. Hiroyasu I. Jacobs D.R. Wentworth D. Neaton J.D. Cohen J.D. for the MRFIT Research Group. 1989 Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial New England Journal of Medicine 320 904 910
17. Ouriel K. 2001 Peripheral arterial disease Lancet 358 1257 1264
18. World Health Organisation. 2002 The World Health Report 2002Reducing Risks, Promoting Healthy Life WHO Geneva
19. Chen Z. Peto R. Collins R. Macmahon S. Lu J. Li W. 1991 Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations British Medical Journal 303 276 282
20. Tolonen H. Keil U. Ferrario M. Evans A. for the WHO MONICA Project. 2004 Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project International Journal of Epidemiology 34 181 192
21. Department of Health. 2004 Prescription Dispensed in the Community, Statistics for 1993 to 2003: England London Department of Health London
22. Department of Health. 2003 Delivering Investment in General Practice: Implementing The New General Medical Services Contract London
23. Wood D. Durrington P. Poulter N. McInnes G. Rees A. Wray R. for the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice Heart 80 S1 S29
24. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension Journal of Hypertensions 21 1011 1053